XLO
Xilio Therapeutics, Inc.
Key Financials
Revenue
$43.8M
↑ 589.9%
Net Income
$-35036000
↑ 39.8%
Operating Income
$-41982000
↑ 30.7%
Total Liabilities
$119.4M
↑ 123.3%
EPS (Diluted)
$-4.19
↓ 284.4%
Shareholders' Equity
$35.3M
↑ 100.4%
Total Assets
$154.7M
↑ 117.6%
Cash & Equivalents
$137.5M
↑ 148.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/16/2026 | View on SEC |
| 3 | 4/16/2026 | View on SEC |
| 8-K | 4/16/2026 | View on SEC |
| 4 | 3/30/2026 | View on SEC |
| S-8 | 3/23/2026 | View on SEC |
| 10-K | 3/23/2026 | View on SEC |
| 8-K | 3/23/2026 | View on SEC |
| 8-K | 3/12/2026 | View on SEC |
| 8-K | 3/9/2026 | View on SEC |
| 8-K | 2/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | XLO |
| Company Name | Xilio Therapeutics, Inc. |
| CIK | 1840233 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-833-1027 |